日本語
English
繁體中文
Tiếng Việt
ไทย
日本語
العربية
한국어
Русский
Español
Português
Oʻzbek tili
ភាសាខ្មែរ
اردو
Français
Italiano
Deutsch
Română
فارسی
Azərbaycan dili
ログイン
サインアップ
0
市場洞察市場洞察

市場洞察

Merck shares fall 9% despite earnings beat, strong demand for top drugs like Keytruda

Amos · 1.7K ビュー

B1AA7B36-B649-4b4f-975F-791ED97034A9

 

Merck reported second-quarter revenue and adjusted earnings that topped estimates as it saw strong sales from its blockbuster cancer drug Keytruda as well as other treatments in its oncology and vaccines portfolios and a new cardiovascular drug. 


The pharmaceutical giant also raised its full-year sales forecast to a range of $63.4 billion to $64.4 billion, however it lowered its adjusted profit guidance to between $7.94 and $8.04 per share.


Shares of Merck fell Tuesday as investors appeared to mull over lighter-than-expected sales of Gardasil.